A Phase 1, Open-Label, Single-Dose, Parallel Group, 2-Part Study to Evaluate the Pharmacokinetics of Bepirovirsen in Adult Participants With Severe or Moderate Renal Impairment Compared to Matched Healthy Control Participants

This is a 2-part study where all participants will receive bepirovirsen. The study will measure how much bepirovirsen from a single dose gets into the blood, and how long it stays in the blood. The purpose of the study is to understand if blood levels of bepirovirsen are different in adults with kidney disease compared to healthy adults who do not have kidney disease.

开始日期2025-09-16

申办/合作机构

GSK Plc

CTRI/2025/03/083590

/ RecruitingN/A

A prospective, multi-centre study (B-Sure) to evaluate long-term durability of treatment response in chronic hepatitis B participants with and without nucleos(t)ide therapy who have participated in a previous bepirovirsen treatment study - B-Sure

开始日期2025-04-08

申办/合作机构

GlaxoSmithKline Research & Development Ltd.

[+1]

NCT06537414

/ Active, not recruiting临床2期

A Phase 2b, Multi-centre, Randomized, Partially Placebo-controlled, Double-blind Study to Investigate the Safety and Efficacy of Sequential Therapy With Daplusiran/Tomligisiran Followed by Bepirovirsen in Participants With Chronic Hepatitis B Virus on Background Nucleos(t)Ide Analogue Therapy (B-United)

The study is intended to evaluate the efficacy and safety of 2 different doses of DAP/TOM followed by bepirovirsen in participants living with CHB on standard of care nucleos(t)ide analogue (NA) therapy. The study also aims to identify an optimal dose of DAP/TOM for sequenced therapy with bepirovirsen for further clinical development and to assess the contribution of DAP/TOM to the sequential regimen.

开始日期2024-11-11

申办/合作机构

GSK Plc

100 项与 Bepirovirsen 相关的临床结果

登录后查看更多信息

100 项与 Bepirovirsen 相关的转化医学

登录后查看更多信息

100 项与 Bepirovirsen 相关的专利（医药）

登录后查看更多信息

项与 Bepirovirsen 相关的文献（医药）

2025-10-01·Clinical Drug Investigation

Emerging Trends and Future Directions in the Development of Anti-hepatitis B Therapies: A Horizon Scanning Review

Review

作者: Wu, Bin ; Yan, Mengxia ; Bao, Yun ; Feng, Hao ; Yao, Kaijie ; Chen, Ying ; Li, Wen

BACKGROUND AND OBJECTIVES:

Chronic hepatitis B virus infection remains a Major global public health challenge, affecting over 254 million individuals and causing substantial mortality owing to the limited curative potential of current therapies. This horizon scanning review aims to comprehensively analyze emerging trends and future directions in novel anti-hepatitis B virus therapeutic development, evaluating their progress and potential to achieve functional or complete cures.

METHODS:

We conducted a systematic horizon scanning review from January 2020 to June 2025, searching databases (PubMed, Embase, the Cochrane Library, China National Knowledge Infrastructure [CNKI], and WanFang), clinical trial registries (ClinicalTrials.gov, EU Clinical Trials Register, World Health Organization International Clinical Trials Registry, Chinese Clinical Trial Registry, and chinadrugtrials.org), hepatology conference abstracts (American Association for the Study of Liver Diseases, European Association for the Study of the Liver), and pharmaceutical company websites. Inclusion criteria focused on studies detailing novel anti-hepatitis B virus treatments, with data extracted on category, target, clinical phase, and discontinuation reasons.

RESULTS:

Our analysis identified 161 unique anti-hepatitis B virus treatments: 75 in clinical trials, 34 in preclinical development, and 52 discontinued post-clinical trials because of safety or insufficient efficacy. The pipeline reveals a diversification of targets, with capsid assembly modulators, therapeutic vaccines, and monoclonal antibodies being most prevalent. Three therapies representing novel mechanisms have reached phase III-bepirovirsen (an antisense oligonucleotide), canocapavir (a capsid assembly modulator), and εPA-44 (a therapeutic vaccine), illustrating diversification of late-stage pipelines; however, 6-month off-treatment endpoints should be interpreted cautiously across modalities until durability is established.

CONCLUSIONS:

The robust and diverse pipeline of novel anti-hepatitis B virus treatments offers promise for improving functional cure rates, but definitive conclusions await longer off-treatment follow-up and durability data. Continued research, rational combination strategies, and global collaboration are crucial to overcome challenges and ensure equitable access to these transformative therapies worldwide.

2025-09-01·Current Opinion in HIV and AIDS

Advancing HIV cure: insights from developing chronic hepatitis b therapies for functional cure

Review

作者: Verma, Ana ; Chung, Raymond T

Purpose of review:

Similarly to HIV, HBV assumes a highly stable nuclear form and becomes integrated into the host genome, posing a significant challenge to complete eradication. The purpose of this review is to highlight the recent progress on various therapies that are being explored to achieve functional cure (FC) of chronic Hepatitis B (CHB).

Recent findings:

The current standard-of-care for CHB is either nucleos(t)ide analogues (NA) or PegIFN-α, but neither alone is sufficient to achieve functional cure. However, NA cessation alone or followed by PegIFN-α shows promise for increasing functional cure rates and decreasing viral relapse rates. While first generation capsid-assembly modulators (CAMs) had virtually no impact on HBsAg, newer, more potent CAMs may have an effect on cccDNA and produce reductions in HBsAg levels. Small-interfering RNAs (siRNAs) can lower HBsAg, but do not appear to result in sustained HBsAg clearance. A similar agent, bepirovirsen (an antisense oligonucleotide), appears to be more effective in producing modest FC rates; this may be due to its possible induction of the innate immune response.

Summary:

Given the persistence of cccDNA and integrated DNA, together with HBsAg-induced immune dysfunction, successful treatment for CHB to induce FC is likely to require a combination of agents that inhibit viral replication, reduce HBsAg levels, and boost the antiviral immune response.

2025-02-01·JOURNAL OF HEPATOLOGY

Sequential Peg-IFN after bepirovirsen may reduce post-treatment relapse in chronic hepatitis B

Article

作者: Gordon, Stuart C. ; Plesniak, Robert ; Coffin, Carla S ; Chak, Eric ; Dixon, Susan ; Ryan, Pablo ; Morozov, Vyacheslav ; Felton, Leigh ; Voloshina, Natalya ; Gankina, Natalya ; Gordon, Stuart C ; Lim, Jessica ; Kendrick, Stuart ; Komori, Atsumasa ; Andreone, Pietro ; Plein, Helene ; Yim, Hyung Joon ; Youssef, Amir S ; Theodore, Dickens ; McGonagle, Grant ; Greene, Thomas ; Tanaka, Yasuhito ; Buti, Maria ; Sagalova, Olga ; Coffin, Carla S. ; McPherson, Stuart ; Lampertico, Pietro ; Janczewska, Ewa ; Lakshminarayanan, Divya ; Xie, Qing ; Cabezas, Joaquín ; Atsukawa, Masanori ; Elston, Rob ; Sheng, Guoping ; Heo, Jeong ; Fujiwara, Kei ; Youssef, Amir ; Paff, Melanie ; Poulin, Sébastien ; Lee, Maximilian

BACKGROUND & AIMS:

Bepirovirsen, an antisense oligonucleotide, induces sustained reductions in hepatitis B surface antigen (HBsAg) and HBV DNA to below the lower limit of quantification (

METHODS:

In this phase IIb, multicentre, open-label trial, participants on stable nucleos(t)ide analogue (NA) therapy were randomised 1:1 to bepirovirsen 300 mg once weekly (plus loading dose on Days 4 and 11) for 24 (Arm 1) or 12 (Arm 2) weeks followed by Peg-IFN 180 μg once weekly for up to 24 weeks, with up to 36 weeks follow-up. Participants continued NA therapy throughout. The primary outcome was the proportion of participants with HBsAg <0.05 IU/ml and HBV DNA

RESULTS:

The intent-to-treat population included 108 participants (Arm 1, n = 55; Arm 2, n = 53). The primary outcome was achieved by 5 (9%) participants in Arm 1 and 8 (15%) in Arm 2. All responders had baseline HBsAg ≤3,000 IU/ml. Indirect comparison with the phase IIb study B-Clear indicates that sequential addition of Peg-IFN may reduce the relapse rates previously observed with bepirovirsen alone. The proportions of participants with adverse events and treatment-related adverse events in both treatment windows were similar between treatment arms.

CONCLUSIONS:

Sequential therapy with bepirovirsen followed by Peg-IFN is tolerable and effective in participants with chronic HBV infection on stable NA therapy. This proof-of-concept trial demonstrates a potential strategy to extend responses to bepirovirsen by reducing relapse.

IMPACT AND IMPLICATIONS:

This phase IIb study investigated whether sequential therapy with bepirovirsen followed by Peg-IFN could improve off-treatment response rates to bepirovirsen alone by converting partial bepirovirsen responders to full responders and/or reducing relapse rates in participants with chronic HBV. These data show that sequential therapy with bepirovirsen followed by Peg-IFN is tolerable and effective; in patients with a bepirovirsen response, sequential treatment with Peg-IFN may help to reduce off-treatment relapses in participants on stable NA. Participants had a similar response during bepirovirsen treatment as seen in B-Clear, with increased response rates in participants with lower baseline HBsAg; all responders to the sequential regimen had baseline HBsAg <3000 IU/mL. As the first study of antisense oligonucleotide-mediated RNA silencing followed by interferon immunomodulation in patients with chronic HBV infection, this study is an important proof-of-concept for sequential therapy, shedding light on the therapeutic potential of utilising immunomodulators following suppression of HBV antigens.

CLINICAL TRIAL NUMBER:

NCT04676724.

195

项与 Bepirovirsen 相关的新闻（医药）

2025-12-03

·生物世界

Nature子刊：悦康药业siRNA新药，有望实现乙肝的功能性治愈

撰文丨王聪编辑丨王多鱼排版丨水成文据估计，全球范围内约有 3.25 亿人慢性感染了乙型肝炎病毒（HBV），尽管已有有效疫苗，HBV 仍导致了每年近 100 万人死亡。HBV 的慢性感染会对肝细胞造成长期损伤，使感染者面临进展性肝病风险，近一半的肝细胞癌是因为 HBV 慢性感染所致。目前，针对慢性乙型肝炎病毒（HBV）感染的治疗方法效果不佳，原因是高循环水平的乙型肝炎表面抗原（HBsAg）导致了免疫耗竭。 2025 年 12 月 1 日，悦康药业宋更申团队在 Nature 子刊 Nature Communications 上发表了题为：An RNA interference therapeutic potentially achieves functional cure of chronic hepatitis B virus infection 的研究论文。该研究表明，靶向乙型肝炎病毒 S 区的 siRNA 药物 KC13-M2G2，有望实现慢性乙型肝炎病毒感染的功能性治愈。在这项最新研究中，研究团队开发了一种靶向乙型肝炎病毒 S 区的小干扰 RNA（siRNA），旨在显著抑制乙型肝炎表面抗原（HBsAg），从而实现宿主免疫恢复。这种名为 KC13-M2G2 的 siRNA 制剂在体外对所有乙型肝炎病毒（HBV）基因型均表现出强大的抗病毒效力。值得注意的是，在多个小鼠模型中，KC13-M2G2 能迅速且持续地降低乙肝表面抗原（HBsAg）和乙肝病毒 DNA 的水平，并伴随乙肝表面抗体的血清学转换，其效果优于处于临床试验阶段的乙型肝炎治疗药物 elebsiran（一款 siRNA 药物）和 bepirovirsen（一款 ASO 药物）。在大鼠和食蟹猴身上进行的毒理学研究显示，KC13-M2G2 具有令人满意的生物安全性。鉴于 elebsiran 和 bepirovirsen 在临床研究中实现的乙型肝炎功能性治愈率不超过 20%，KC13-M2G2 作为一种有潜力的候选药物，有望在临床应用中表现出更出色的乙型肝炎功能性治愈效果。论文链接： https://www.nature.com/articles/s41467-025-66876-5 设置星标，不错过精彩推文开放转载欢迎转发到朋友圈和微信群微信加群为促进前沿研究的传播和交流，我们组建了多个专业交流群，长按下方二维码，即可添加小编微信进群，由于申请人数较多，添加微信时请备注：学校/专业/姓名，如果是PI/教授，还请注明。点在看，传递你的品味

2025-12-02

·永盛财经

临床揭盲定生死？乙肝治愈曙光引爆股价！广生堂2026上半年股价异动，机构持仓增减背后的博弈逻辑

2026年上半年股价波动核心分析1. 波动阶段划分及关键节点（结合时间线）阶段一：1-2月预热上涨期（股价区间：95元-120元，涨幅26.3%）核心驱动因素为乙肝创新药临床进展的预期升温。广生堂核心管线"GST-HG141+GST-HG131"三联疗法作为国内首个乙肝功能性治愈组合方案，此前已获北京市优化审评审批试点支持，市场普遍预期其将于2025年底至2026年Q1揭盲。叠加2025年6月数据显示，31家主力机构持仓量达4872.91万股，占流通A股35.64%，较上一周期净增仓50.58万股，新进入机构23家带来增量资金，市场情绪提前反应，股价呈现稳步攀升态势。此阶段换手率维持在1.5%-2%区间，成交额从日均1.8亿元放大至2.5亿元，资金做多意愿明确。阶段二：3月震荡调整期（股价区间：115元-125元，振幅8.7%）波动核心源于政策面与临床预期的博弈。3月1日《中药生产监督管理专门规定》正式施行，虽广生堂核心业务为化学制剂，但市场担忧医药行业监管收紧的传导效应，尤其是规定中"中药材GAP溯源要求"可能增加药企供应链成本。同期，乙肝创新药领域出现竞品扰动，GSK宣布其乙肝ASO药物Bepirovirsen预计2026年提交上市申请，部分资金出于竞争顾虑选择短期止盈。不过，广生堂同期披露的2025年业绩预告显示，已上市恩替卡韦等产品基层覆盖率超60%，集采中标产品贡献稳定现金流，为股价提供支撑，使得调整幅度受限。阶段三：4-6月业绩与临床双驱动上涨期（股价区间：120元-145元，涨幅20.8%） 4月中旬，广生堂正式公布三联疗法II期临床揭盲数据，显示HBsAg清除率达32%，显著高于现有疗法，达到预设临床终点，该数据在AASLD 2026学术会议上获权威认可，成为股价暴涨的直接导火索，单日涨幅达15.3%，成交额激增至5.2亿元，换手率突破5%。5-6月，业绩兑现进一步强化上涨逻辑，2026年一季报显示公司营收同比增长42%，其中创新药研发投入占比提升至35%，同时社保基金新进成为十大流通股东，传递长期投资信心。尽管6月下旬受大盘医药板块回调影响，股价短暂回落至130元，但很快在机构资金护盘下回升，期末收于142元，较年初涨幅达49.5%。2. 核心驱动因素深度解析（1）研发管线：决定股价估值的核心变量广生堂的估值逻辑已从"仿制药企"转向"创新药龙头"，核心依赖乙肝功能性治愈赛道的突破。三联疗法作为国内首个进入关键临床阶段的组合方案，其临床数据直接决定估值溢价空间。揭盲数据公布前，市场按"临床成功概率"给予估值；数据落地后，估值切换至"商业化前景"，按全球乙肝2.8亿患者的市场规模测算，该疗法若成功上市，峰值销售额有望突破50亿元，对应股价估值中枢上移至150元区间。此外，公司布局的流感、新冠广谱抗病毒药物GST-HG221临床前数据优异，形成"乙肝+广谱抗病毒"双轮驱动，为股价提供长期想象空间。（2）机构持仓：短期股价波动的直接推手 2025年6月至2026年6月，主力机构持仓呈现"新进入者增多、集中度提升"特征。31家机构中，23家为新进入者，持有1272.92万股，占流通股9.3%，其中不乏社保基金、QFII等长期资金。机构操作节奏与股价波动高度同步：1-2月新机构建仓推动股价上涨；3月部分短期基金减仓引发震荡；4月临床数据公布后，前期减仓机构回补仓位，形成共振上涨。从筹码分布看，6月底90%筹码集中在120-150元区间，平均成本132元，获利盘占比达87%，筹码结构相对稳定，为后续股价提供支撑。（3）行业环境：政策与竞品的双重影响政策面呈现"分化效应"：一方面，医药创新政策持续利好，北京市优化审评审批试点等政策加速创新药上市进程；另一方面，《中药生产监督管理专门规定》带来的监管预期升温，以及集采扩围可能对仿制药业务的压价影响，形成短期扰动。竞品方面，GSK的Bepirovirsen、浩博医药的AHB-137等乙肝创新药相继进入后期临床，市场对乙肝赛道"先发优势"的竞争尤为关注，广生堂凭借三联疗法的组合优势，在国内竞争中占据先机，成为机构资金优先配置标的。3. 风险提示与投资逻辑总结（1）主要风险点临床进展不及预期：若三联疗法III期临床数据未达预期，或审批进度延迟，将直接导致估值下修；竞品竞争加剧：若外资药企产品率先上市，可能挤压广生堂市场份额；政策风险：集采扩围至创新药领域或医保谈判压价超预期，影响盈利空间。（2）投资逻辑总结 2026年上半年广生堂股价呈现"预期驱动-政策扰动-数据兑现"的清晰波动脉络，核心投资逻辑在于乙肝功能性治愈赛道的稀缺性与临床进展的确定性。短期看，三联疗法III期临床启动时间、竞品上市进度为关键观察点；长期看，创新药管线商业化能力与现有仿制药业务的现金流支撑，将决定股价的长期估值中枢。对于投资者而言，可重点关注临床数据披露、机构持仓变化等关键节点，把握"回调布局、数据验证后加仓"的投资节奏。

2025-12-02

·今日头条

2026年乙肝功能性治愈新药将上市多款创新药有望终结终身用药

2026年将成为乙肝治疗领域的“破冰之年”——多款瞄准“功能性治愈”的创新药即将上市，不仅有望终结“终身用药”的困境，更让“清除病毒大本营”（cccDNA）从医学难题变为临床可能。从全球首款反义寡核苷酸（ASO）药物，到国产“抑制+清除”联合疗法，再到填补肝纤维化空白的1类新药，乙肝患者的“治愈梦”正加速照进现实。 ## 一、GSK836：全球首款功能性治愈ASO药物将至作为全球进度最快的乙肝功能性治愈候选药，葛兰素史克（GSK）的Bepirovirsen（GSK836）预计2026年向中国、美国、日本等国提交上市申请。这款新型ASO药物的核心优势在于“精准打击”：通过靶向HBV RNA，一方面阻断病毒复制、降解核心抗原减少载量，另一方面降低HBsAg水平以激活患者自身免疫系统。临床数据显示，其与聚乙二醇干扰素α-2a（Peg-IFN）序贯治疗的完全应答（CR）患者，功能性治愈可持续长达1年；而B-Sure长期研究进一步证实，基线HBsAg≤1000IU/mL的HBeAg阴性CR患者，疗效尤为持久。更关键的是，GSK836国内Ⅲ期临床已完成患者招募，近期将公布研究数据并启动上市申报，有望成为国内首个获批的“功能性治愈”乙肝药物。 ![](blockview://markdown-image-tos-cn-i-tt/41367fbef7b9450cb9d9b1417b4c1981) ## 二、国产联合疗法：“堵源头+清库存”刷新治愈纪录国内科研团队的“组合拳”同样惊艳。南方医院研发的HT-101+HT-102联合疗法，凭借“抑制+清除”的闭环机制，在Ⅱ期临床中创造了20周90%的HBsAg清除率——HT-101作为GalNAc偶联小干扰RNA（siRNA），精准沉默肝细胞内HBV RNA，从源头阻止HBsAg产生；HT-102则是全人源单克隆抗体，快速清除血液中已有的HBsAg。即便是表面抗原超过1000IU/ml的难治患者，治疗20周后也降至极低水平，且安全性良好（仅轻微注射部位红肿，肝肾功能无影响）。预计2026年上半年将公布停药后随访结果，有望成为国内患者的“治愈新选择”。此外，口服表面抗原抑制剂GST-HG131也表现突出，其联合治疗组最高90%的清除率，解决了部分患者“怕打针、依从性差”的问题。 ## 三、氟非尼酮：填补乙肝肝纤维化治疗空白除了功能性治愈，针对乙肝并发症的新药也将亮相。国内首款乙肝肝纤维化1类新药氟非尼酮，已纳入国家药监局突破性治疗品种，Ⅲ期临床提前启动，预计2026年上市。这款药物针对乙肝患者常见的肝纤维化问题，填补了国内百亿级市场空白，预计峰值收入将突破150亿元，为乙肝患者的长期预后提供关键支持。 2026年的乙肝新药潮，不仅是药物研发的突破，更是“功能性治愈”从“理论”到“临床”的跨越。无论是GSK836的“精准靶向”，还是国产联合疗法的“闭环策略”，都指向同一个方向——乙肝不再是“终身疾病”。而2025年国家医保局明确的“加快创新药纳入医保”政策，更让这些新药的“可及性”成为可能。对于千万乙肝患者而言，2026年，或许就是“告别药片”的起点。

100 项与 Bepirovirsen 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	-	DB16202

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
慢性乙型肝炎	临床3期	美国	GSK Plc	2022-12-06
慢性乙型肝炎	临床3期	中国	GSK Plc	2022-12-06
慢性乙型肝炎	临床3期	日本	GSK Plc	2022-12-06
慢性乙型肝炎	临床3期	阿根廷	GSK Plc	2022-12-06
慢性乙型肝炎	临床3期	澳大利亚	GSK Plc	2022-12-06
慢性乙型肝炎	临床3期	巴西	GSK Plc	2022-12-06
慢性乙型肝炎	临床3期	保加利亚	GSK Plc	2022-12-06
慢性乙型肝炎	临床3期	加拿大	GSK Plc	2022-12-06
慢性乙型肝炎	临床3期	法国	GSK Plc	2022-12-06
慢性乙型肝炎	临床3期	德国	GSK Plc	2022-12-06

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT06058390 (CTgov)	临床1期	乙型肝炎	160	Bepirovirsen (Bepirovirsen 300 mg Vial by HCP)	繭遞襯餘窪糧鏇遞夢選(憲簾鹽鬱顧遞選繭選築) = 夢繭選鹽繭淵鑰鏇鏇願積鬱餘製憲鏇襯鹽衊簾 (艱廠醖淵顧蓋選製鏇淵, 0.049) 更多	-	2025-07-18
				Bepirovirsen (Bepirovirsen 300 mg PFS SSD by HCP)	繭遞襯餘窪糧鏇遞夢選(憲簾鹽鬱顧遞選繭選築) = 壓構繭鑰憲鹹網網簾餘積鬱餘製憲鏇襯鹽衊簾 (艱廠醖淵顧蓋選製鏇淵, 0.048) 更多
NCT04676724 (B-Together, Pubmed \| J Hepatol)	临床2期	慢性乙型肝炎 HBsAg \| HBV DNA	108	Bepirovirsen 300 mg once weekly for 24 weeks	鏇糧簾壓壓獵築繭願製(鏇鏇顧選願衊糧夢蓋鹹) = The proportions of participants with adverse events and treatment-related adverse events in both treatment windows were similar between treatment arms 顧蓋齋製糧廠醖製繭範 (蓋製鹽鬱構選網廠鹽膚 )	积极	2025-02-01
				Bepirovirsen 300 mg once weekly for 12 weeks
NCT04544956 (B-Fine, CTgov)	临床2期	慢性乙型肝炎	12	Nucleos(t)ide therapy+GSK3228836	積積築鹽鹹蓋醖廠構製 = 鏇顧願夢鏇糧餘窪淵窪鑰鹽鹹憲鹹繭淵構鹽築 (廠窪網範餘築鹽餘餘鏇, 築衊構廠鏇選廠夢艱蓋 ~ 蓋選繭憲網廠觸夢繭製) 更多	-	2024-12-19
NCT04971928 (B-Assured, Pubmed) 人工标引	临床1期	慢性乙型肝炎	24	Bepirovirsen (hepatic impairment participants)	淵願獵獵製鹹糧蓋獵壓(壓鹹選憲壓鹽艱觸襯網): Geometric Mean Ratio = 0.69 更多	积极	2024-09-13
				Bepirovirsen (healthy participants)
NCT04676724 (B-Together \| B-Together study, CTgov)	临床2期	慢性乙型肝炎	108	PegIFN+GSK3228836 (GSK3228836 300 mg (24 Weeks) + PegIFN 180 mcg (24 Weeks))	憲構繭蓋鬱築憲糧齋構 = 積壓憲繭鏇衊廠繭廠糧窪憲壓顧淵繭憲遞築壓 (顧簾衊廠淵襯構廠遞醖, 鑰壓製構鹽齋艱製糧鹽 ~ 製淵鏇積顧簾願鹹鬱壓) 更多	-	2024-05-02
				PegIFN+GSK3228836 (GSK3228836 300 mg (12 Weeks) + PegIFN 180 mcg (24 Weeks))	製選鬱築夢淵鹹窪網衊 = 淵顧繭醖網觸簾窪範蓋廠窪壓製襯獵糧膚範蓋 (襯鹽鏇製蓋獵餘鏇願積, 淵鹽積鹹簾顧網遞鑰廠 ~ 構顧選蓋願糧衊膚鹽憲) 更多
NCT04676724 \| EUCTR2020-002979-35-GB (B-TOGETHER, AASLD2023)	临床2期	慢性乙型肝炎 HBsAg \| HBV DNA \| ALT	108	Arm 1 (BPV 300 mg for 24 weeks + PegIFN 180 mcg QW for 24 weeks)	壓遞遞鑰願獵糧簾網範(衊憲願觸積憲窪獵膚顧) = 遞壓窪積鬱鹹鹽艱範襯淵餘鹽廠獵顧鹹鬱鹽糧 (遞獵範獵鹹憲鑰憲獵鬱 )	-	2023-11-10
NCT04676724 (B-Together, AASLD2023)	临床2期	慢性乙型肝炎	-	Arm 1 (BPV 24 wk)	鹹簾繭積構獵鏇鑰糧襯(網淵鏇壓醖簾夢醖積蓋) = 選齋鹹淵鏇構鹽鑰衊選壓淵憲窪餘餘醖齋築觸 (構顧鑰構夢衊觸願範願 )	-	2023-11-10
				Arm 2 (BPV 12 wk)	鹹簾繭積構獵鏇鑰糧襯(網淵鏇壓醖簾夢醖積蓋) = 製衊遞膚膚製齋襯鏇醖壓淵憲窪餘餘醖齋築觸 (構顧鑰構夢衊觸願範願 )